Advertisement
New Zealand markets closed
  • NZX 50

    11,938.08
    +64.04 (+0.54%)
     
  • NZD/USD

    0.6012
    +0.0049 (+0.83%)
     
  • NZD/EUR

    0.5579
    +0.0023 (+0.42%)
     
  • ALL ORDS

    7,897.50
    +48.10 (+0.61%)
     
  • ASX 200

    7,629.00
    +42.00 (+0.55%)
     
  • OIL

    77.99
    -0.96 (-1.22%)
     
  • GOLD

    2,310.10
    +0.50 (+0.02%)
     
  • NASDAQ

    17,890.79
    +349.25 (+1.99%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • Dow Jones

    38,675.68
    +450.02 (+1.18%)
     
  • DAX

    18,001.60
    +105.10 (+0.59%)
     
  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • NZD/JPY

    91.9390
    +0.3640 (+0.40%)
     

Is Moderna Stock a No-Brainer Buy With Omicron Boosters on the Way?

This should be especially good news for Moderna (NASDAQ: MRNA). The first hurdle is that Moderna must obtain FDA Emergency Use Authorization (EUA) for its omicron booster. The second hurdle for Moderna is to secure an additional supply deal with the U.S. government that includes omicron boosters.